The National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers to reduce the Maximum Retail Price (MRP) of Trastuzumab, Osimertinib, and Durvalumab. The Ministry of Chemicals and Fertilizers has issued a press release on this decision on October 29, 2024.
It may be recalled that the NPPA has issued an Office Memorandum dated October 28, 2024 requiring manufacturers and marketing companies selling these drugs to revise their MRPs.
This reduction in MRP is a result of the government’s initiative to exempt these drugs from customs duty and reduce GST rates. The Department of Revenue, Ministry of Finance, has issued notifications to implement these changes.
The NPPA’s order mandates manufacturers to issue revised price lists .They are also required to issue a price list or supplementary price list to the dealers, State Drugs Controllers and the Government indicating changes and to submit information regarding price change to NPPA through Form-II/ Form V.
